📰 Merck Sharp News
Page 46 - Merck Sharp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Merck Sharp. Real-time updates on events, politics, business and more.
February 28, 2023
Adding olaparib to first-line treatment with abiraterone extends overall survival in patients with metastatic castration-resistant prostate cancer.
February 28, 2023
The European Commission will publish proposals next month updating its pharmaceutical regulation.
February 27, 2023
/PRNewswire/ -- The prevalence of Alzheimers disease has been rising over the past few years, which prompts the growing demand for treatment options. The...
February 27, 2023
The global genital warts (condyloma acuminatum) market is predicted to be worth US$ 1.87 billion in 2023, rising to US$ 3 billion by 2033 at a CAGR of 4.84%.The global market is expected to benefit from government initiatives and increasing financing for cancer research. The rising expenditure on R&D connected with...
February 24, 2023
The global Biliary Tract Cancers (BTCs) treatment market is expected to witness steady growth in the coming years, according to a new report published by a leading market research firm. The report provides insights into the current market scenario, trends, drivers, challenges, and opportunities in the BTCs treatment...
February 22, 2023
In 2023, the global Treatment-Resistant Depression Treatment Market is anticipated to be worth US$ 1.69 billion. Because of the rising frequency of depression and anxiety disorders in adults, as well as the ageing population, the global demand for treatment-resistant depression treatment is expected to expand at a C...
February 21, 2023
RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LAGEVRIO™ (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual with COVID-19. The Phase 3...
February 21, 2023
21.02.2023 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LAGEVRIO (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual ...
February 17, 2023
A joint venture of Onyx Equities LLC and Machine Investment Group LLC acquired the 108-acre Merck HQ property in Kenilworth.
February 17, 2023
Adding olaparib to first-line treatment with abiraterone extends overall survival in patients with metastatic castration-resistant prostate cancer.